$2.51
+0.13
(+5.46%)▲
Revenue is down for the last 3 quarters, 4.23M → 2.99M (in $), with an average decrease of 15.9% per quarter
Netprofit is down for the last 2 quarters, -28.22M → -31.27M (in $), with an average decrease of 10.8% per quarter
In the last 1 year, Idexx Laboratories, Inc. has given 21.6% return, outperforming this stock by 84.3%
In the last 3 years, Idexx Laboratories, Inc. has given 48.5% return, outperforming this stock by 129.6%
7.97%
Downside
Day's Volatility :7.97%
Upside
0.0%
38.25%
Downside
52 Weeks Volatility :82.64%
Upside
71.89%
Period | DermTech Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -33.95% | 0.7% | -7.0% |
6 Months | -6.69% | -7.9% | -6.5% |
1 Year | -62.7% | -2.0% | -6.8% |
3 Years | -81.11% | 25.4% | 24.7% |
Market Capitalization | 74.0M |
Book Value | $3.45 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.85 |
Wall Street Target Price | 5.1 |
Profit Margin | 0.0% |
Operating Margin TTM | -840.65% |
Return On Assets TTM | -36.01% |
Return On Equity TTM | -75.85% |
Revenue TTM | 14.3M |
Revenue Per Share TTM | 0.47 |
Quarterly Revenue Growth YOY | -6.5% |
Gross Profit TTM | 647.0K |
EBITDA | -118.3M |
Diluted Eps TTM | -3.85 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.75 |
EPS Estimate Next Year | -2.91 |
EPS Estimate Current Quarter | -0.91 |
EPS Estimate Next Quarter | -0.88 |
What analysts predicted
Upside of 103.19%
Sell
Neutral
Buy
DermTech Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() DermTech Inc | -14.19% | -6.69% | -62.7% | -81.11% | -74.77% |
![]() IDEXX Laboratories, Inc. | 0.53% | 7.93% | 21.61% | 48.46% | 114.73% |
![]() Agilent Technologies Inc. | -13.57% | -25.32% | -9.95% | 28.76% | 83.43% |
![]() Thermo Fisher Scientific, Inc. | -4.49% | -7.75% | -8.9% | 48.36% | 142.51% |
![]() Danaher Corp. | -4.16% | -15.15% | -14.85% | 39.37% | 128.42% |
![]() IQVIA Holdings Inc. | 7.2% | -8.62% | -9.58% | 31.31% | 96.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() DermTech Inc | NA | NA | NA | -3.75 | -0.76 | -0.36 | 0.0 | 3.45 |
![]() IDEXX Laboratories, Inc. | 56.2 | 56.2 | 7.21 | 9.69 | 0.94 | 0.22 | 0.0 | 10.13 |
![]() Agilent Technologies Inc. | 26.91 | 26.91 | 2.36 | 5.63 | 0.25 | 0.1 | 0.01 | 18.96 |
![]() Thermo Fisher Scientific, Inc. | 33.19 | 33.19 | 4.28 | 23.68 | 0.14 | 0.05 | 0.0 | 109.55 |
![]() Danaher Corp. | 24.72 | 24.72 | 3.24 | 9.38 | 0.14 | 0.06 | 0.0 | 68.31 |
![]() IQVIA Holdings Inc. | 35.16 | 35.16 | 1.48 | 10.42 | 0.18 | 0.05 | 0.0 | 31.98 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() DermTech Inc | Buy | $74.0M | -74.77% | NA | 0.0% |
![]() IDEXX Laboratories, Inc. | Buy | $38.6B | 114.73% | 56.2 | 20.38% |
![]() Agilent Technologies Inc. | Buy | $35.3B | 83.43% | 26.91 | 19.09% |
![]() Thermo Fisher Scientific, Inc. | Buy | $196.1B | 142.51% | 33.19 | 13.75% |
![]() Danaher Corp. | Buy | $169.4B | 128.42% | 24.72 | 22.4% |
![]() IQVIA Holdings Inc. | Buy | $36.5B | 96.53% | 35.16 | 7.28% |
RTW INVESTMENTS, LLC
Vanguard Group Inc
BlackRock Inc
King Luther Capital Management Corp
EPIQ PARTNERS, LLC
White Pine Capital LLC
DermTech Inc’s price-to-earnings ratio stands at None
Read MoreDermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech's mission is to transform dermatology with its non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.
Organization | DermTech Inc |
Employees | 278 |
CEO | Dr. John D. Dobak M.D. |
Industry | Finance |
PowerShares SP MidCap Low Volatility ETF
$49.79
+0.48%
SPDR NYSE Technology ETF
$131.78
+1.16%
ProShares UltraPro Dow30 ETF
$53.74
+1.15%
Teucrim Soybean Fund
$24.43
+1.52%
CRESCENT CAPITAL BDC INC
$13.63
+1.11%
Fusion Pharmaceuticals Inc
$5.02
-1.57%
AMC Networks Inc.
$11.41
+0.88%
EVGO INC CL A
$4.01
+1.26%
CONNECT BIOPHARMA HOLDINGS L
$1.11
+2.42%